CA 72.4 è un marcatore tumorale utilizzato per monitorare principalmente i tumori allo stomaco, ma anche quelli dell’ovaio e del colon. Si tratta di una glicoproteina le cui elevazioni possono indicare la presenza di tumori, ma anche di alcune patologie benigne come il Morbo di Crohn o gastriti.
È una glicoproteina ad alto peso molecolare, appartenente alla famiglia delle mucine. Viene utilizzata principalmente per la diagnosi e il monitoraggio dei tumori, in particolare allo stomaco. L’aumento dei livelli di CA 72.4 è associato a tumori dell’ovaio, del polmone, del colon, della mammella, dello stomaco e del pancreas. Può aumentare anche in condizioni non tumorali, come il Morbo di Crohn, gastriti, coliti, esofagiti e malattie infiammatorie croniche intestinali. Il test è utile per monitorare l’andamento della malattia e la risposta al trattamento nei pazienti con diagnosi di cancro.
Può essere utilizzato per valutare il rischio di recidiva in pazienti con storia di cancro allo stomaco, secondo studi scientifici.
CA 72.4 is a tumor marker used to monitor primarily stomach cancers, but also ovarian and colon cancers. It is a glycoprotein whose elevations can indicate the presence of tumors, but also of some benign pathologies such as Crohn’s disease or gastritis.
It is a high molecular weight glycoprotein, belonging to the mucin family. It is mainly used for the diagnosis and monitoring of tumors, particularly in the stomach. Increased CA 72.4 levels are associated with ovarian, lung, colon, breast, stomach, and pancreatic cancers. It can also increase in non-tumor conditions, such as Crohn’s disease, gastritis, colitis, esophagitis and chronic inflammatory bowel disease. The test is useful for monitoring disease progress and response to treatment in patients diagnosed with cancer.
It can be used to assess the risk of recurrence in patients with a history of stomach cancer, according to scientific studies.
It is a high molecular weight glycoprotein, belonging to the mucin family. It is mainly used for the diagnosis and monitoring of tumors, particularly in the stomach. Increased CA 72.4 levels are associated with ovarian, lung, colon, breast, stomach, and pancreatic cancers. It can also increase in non-tumor conditions, such as Crohn’s disease, gastritis, colitis, esophagitis and chronic inflammatory bowel disease. The test is useful for monitoring disease progress and response to treatment in patients diagnosed with cancer.
It can be used to assess the risk of recurrence in patients with a history of stomach cancer, according to scientific studies.